ArticleInternational journal of retina and vitreous2026
Do we need to hold aspirin before vitreoretinal surgery? A systematic review and meta-analysis.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the safety of aspirin continuation versus discontinuation in patients undergoing vitreoretinal surgery by assessing hemorrhagic complications and visual outcomes.
methodsThe review protocol was prospectively registered in PROSPERO (CRD420251270694). A systematic review and meta-analysis was conducted following PRISMA guidelines. PubMed, Scopus, Ovid, and Web of Science were searched from inception through August 31, 2025. Studies comparing aspirin continuation versus discontinuation or no aspirin use in adult patients undergoing vitreoretinal surgery were included. The primary outcome was vitreous hemorrhage. Secondary outcomes included hyphema, subconjunctival hemorrhage, subretinal hemorrhage, choroidal hemorrhage, retinal hemorrhage, and visual acuity changes. Risk ratios (RR) with 95% confidence intervals (CI) were calculated using random-effects models. Quality assessment was performed using the Newcastle-Ottawa Scale, and certainty of evidence was rated using the GRADE framework.
resultsSeven studies comprising 2,889 surgical procedures (2,873 patients) were included. Aspirin continuation was not associated with significantly increased risk of vitreous hemorrhage (RR 1.55, 95% CI: 0.73–3.29, p = 0.253, I²=61.7%), hyphema (RR 1.52, 95% CI: 0.56–4.17, p = 0.415, I²=0.0%), subconjunctival hemorrhage (RR 1.20, 95% CI: 0.58–2.48, p = 0.622, I²=0.0%), subretinal hemorrhage (RR 1.06, 95% CI: 0.15–7.63, p = 0.956, I²=82.4%), choroidal hemorrhage (RR 2.07, 95% CI: 0.81–5.24, p = 0.127, I²=0.0%), retinal hemorrhage (RR 1.68, 95% CI: 0.33–8.52, p = 0.532, I²=73.6%), or postoperative visual acuity (MD = 0.26 logMAR, 95% CI: −0.005 to 0.52; p = 0.055). Included studies were rated as moderate to high quality on the Newcastle-Ottawa Scale. GRADE certainty of evidence was rated as low to very low across all outcomes.
conclusionsAspirin continuation appears safe in vitreoretinal surgery, with low risk of hemorrhagic complications. Given aspirin’s thrombotic benefits, it can likely be continued in most patients. However, this conclusion, based on low-certainty evidence, should be interpreted with caution and requires confirmation from high-quality prospective randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.